-
The medical insurance adjustment will be completed before the end of the year. The industry recommends grasping the investment opportunities of innovative drugs and CXO
Time of Update: 2021-12-08
After the price drop, third-party data pointed out that the drugs included in the medical insurance catalog after medical insurance negotiations from 2017 to 2019 have achieved 128%, 337%, and 39% growth in sales in 2020 relative to the year of inclusion .
-
The State Food and Drug Administration approves the listing of Yinqiao Qingre Tablets, an innovative Chinese medicine drug
Time of Update: 2021-12-08
On November 10, the State Food and Drug Administration issued an announcement stating that it had recently approved the registration application for Yinqiao Qingre tablets . Jiangsu Kangyuan Pharma
-
Blockbuster SGLT2 inhibitors are eligible for FDA priority review, which is expected to benefit two types of heart failure patients
Time of Update: 2021-12-08
Reference materials:[1] US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance® for adults with heart failure independent of left ventricular ejection fraction.
-
1.2 million injections of anti-cancer drugs may miss medical insurance
Time of Update: 2021-12-08
It is worth noting that from November 10 until the end of the medical insurance negotiations, the representative of Fosun Kate, a manufacturer of "sky-priced anti-cancer drugs" with a high price of 1.
-
The API industry welcomes the new policy, the industry: good for the pharmaceutical equipment industry
Time of Update: 2021-12-08
This may help force domestic API production equipment manufacturers to increase R&D investment, continue to obtain new breakthroughs in the high-end field, and promote the better development of the API industry .
-
The biopharmaceutical industry accelerates its development towards high quality, and the performance of pharmaceutical machinery companies may usher in new growth
Time of Update: 2021-12-08
For example, Jiangsu Province recently issued "Several Policies and Measures on Promoting the High-Quality Development of the Province’s Biomedicine Industry", which clearly stated that by 2024, the basic capabilities of Jiangsu’s biomedical industry and the modernization level of the industrial chain must continue to be improved.
-
Or focus on core business, or increase market share...Pharmaceutical companies will sell more frequently
Time of Update: 2021-12-08
Another example is Tianyao's recent announcement that Fosun Pharma intends to transfer its 25 shares of Tianjin Pharmaceutical Group, the controlling shareholder of the company, to Jinyao Group, the indirect controlling shareholder of the company, at a price of 1.
-
Targeting both domestic and foreign markets, pharmaceutical companies are actively deploying antidepressant drugs
Time of Update: 2021-12-08
According to relevant statistics, in 2019, the sales of terminal antidepressant drugs in public medical institutions in China increased by 10% year-on-year, exceeding 9 billion yuan .
According to statistics, there are currently 4 new antidepressant drugs developed and approved by domestic pharmaceutical companies.
-
The pharmaceutical and biological sector has fallen by 7% since October. Is there still a chance to get on the car?
Time of Update: 2021-12-08
Judging from the attitudes of many fund managers and industry researchers, they generally believe that the current valuation of the pharmaceutical sector is at a relatively reasonable level, and there are more structural opportunities in the sector that are worth grasping .
-
The pharmaceutical equipment industry ushered in a new round of growth, and the high-end market has become a new growth point for performance
Time of Update: 2021-12-08
It clearly stated that in the future, it will continue to implement the development strategy of "one vertical, one horizontal and one platform", leverage the synergy effects of various subsidiaries, increase investment in research and development and advanced manufacturing technology, and actively seize market opportunities in AI and intelligent equipment, and Steadily promote the construction of production capacity, and strive to achieve the strategic goal of reaching 20 billion yuan in sales in 2030 .
-
The 2021 national talks are on the spot: a variety of PD-(L)1 confrontation BMSs are absent; CAR-T has not appeared in ADC, small molecule inhibitors are hotly talked...
Time of Update: 2021-12-08
Although the final results of the negotiations have not yet been released, the share prices of domestic PD-1 companies Hengrui, Junshi, Cinda, and BeiGene have soared after the medical insurance negotiations in the morning.
-
National Center for Integrated Traditional Chinese and Western Medicine (General Hospital) Setting Standards Released
Time of Update: 2021-12-08
On November 8, the National Health Commission and the State Administration of Traditional Chinese Medicine jointly issued the standards for the establishment of the National Integrated Traditional Chinese and Western Medicine Center (General Hospital), and the relevant standards for the establishment of the National Integrated Traditional Chinese and Western Medicine Center by the Hospital of Integrated Traditional Chinese and Western Medicine will be formulated separately .
-
Johnson & Johnson's blockbuster drug daratumumab gains new indications in China
Time of Update: 2021-12-08
Retrieved Nov 12, 2021, from https://® (Daratumumab) Shows Overall Survival Benefit and Continued Improvement in Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant.
Retrieved Dec 9, 2019, from https:// darzalex-daratumumab-shows-overall-survival-benefit-and-continued-improvement-in-progression-free-survival-in-patients-with-newly-diagnosed-multiple-myeloma-who-are-ineligible-for-transplant
-
Under the continuous changes in the pharmaceutical market, pharmaceutical companies are accelerating the promotion of product reviews
Time of Update: 2021-12-08
According to relevant national policies, the types, quality and efficacy of drugs that have passed the consistency evaluation are equivalent to the original research products, and appropriate support will be given in terms of medical insurance payment and procurement by medical institutions .
-
The policy is to vacate the cage and change the bird, and the domestic innovative drugs may usher in a dividend period in the next ten years
Time of Update: 2021-12-08
In addition, industry insiders also said that in recent years, the introduction of policies such as import "zero tariff", review and approval system reform, consistency evaluation, and medical insurance negotiations are forcing pharmaceutical companies to develop in the direction of innovation .
-
Guangdong and Qinghai issued notices on drug quality sampling inspections for 7 varieties and 8 batches that did not meet the requirements
Time of Update: 2021-12-08
From November 10th to 11th, the drug regulatory bureaus of Guangdong and Qinghai provinces issued drug random inspection information notices. The notice showed that 47 batches of 39 varieties in Guan
-
Shanghai Songjiang Biopharmaceutical Industry Develops High-Quality Acceleration
Time of Update: 2021-12-08
As of June this year, there are nearly 3,000 companies related to the biomedical industry in Songjiang District, of which more than 1,800 were registered after the start of the construction of the Yangtze River Delta G60 Science and Technology Innovation Corridor in 2016, achieving a five-year increase of 1.
-
20 domestically-made innovative drugs may undergo initial medical insurance negotiations to accelerate drug volume
Time of Update: 2021-12-08
According to the industry, the anti-tumor drug PD-1 monoclonal antibody is still the focus of medical insurance negotiations, but among domestic products, the companies and varieties that are eligible to participate in the medical insurance negotiations in 2021 are the 4 varieties that participated in the medical insurance negotiations last year, and the competitive landscape is still relatively relaxed .
-
Research Progress of Glucose Sensitive Insulin Intelligent Drug Delivery System
Time of Update: 2021-12-08
The pH-triggered insulin release system utilizes the gluconic acid produced when GOx oxidizes glucose, causing local pH to decrease, which in turn triggers changes in the carrier structure (dissociation, swelling, or collapse), and ultimately leads to drug release .
-
In the future, the pace of overseas listing of new domestic drugs will continue to accelerate
Time of Update: 2021-12-08
On October 26, Lunan Pharmaceutical received an approval letter from the US FDA regarding the addition of the Shandong New Times Pharmaceuticals production site to the rosuvastatin calcium tablets ANDA (a brief application for new drugs), marking the ANDA rosuvastatin calcium produced by Lunan Pharmaceuticals The film can be sold in the US market .
